BIYKEM BOZKURT to Tumor Necrosis Factor-alpha
This is a "connection" page, showing publications BIYKEM BOZKURT has written about Tumor Necrosis Factor-alpha.
Connection Strength
0.470
-
Results of targeted anti-tumor necrosis factor therapy with etanercept (ENBREL) in patients with advanced heart failure. Circulation. 2001 Feb 27; 103(8):1044-7.
Score: 0.126
-
Pathophysiologically relevant concentrations of tumor necrosis factor-alpha promote progressive left ventricular dysfunction and remodeling in rats. Circulation. 1998 Apr 14; 97(14):1382-91.
Score: 0.103
-
Biomarkers of inflammation in heart failure. Heart Fail Rev. 2010 Jul; 15(4):331-41.
Score: 0.060
-
Effect of the soluble TNF-antagonist etanercept on tumor necrosis factor bioactivity and stability. Clin Transl Sci. 2008 Sep; 1(2):142-5.
Score: 0.053
-
Tumor necrosis factor-alpha and myocardial remodeling in progression of heart failure: a current perspective. Cardiovasc Res. 2002 Mar; 53(4):822-30.
Score: 0.034
-
The role of anti-cytokine therapy in the failing heart. Heart Fail Rev. 2001 Mar; 6(2):143-51.
Score: 0.031
-
Safety and efficacy of a soluble P75 tumor necrosis factor receptor (Enbrel, etanercept) in patients with advanced heart failure. Circulation. 1999 Jun 29; 99(25):3224-6.
Score: 0.028
-
An overview of tumor necrosis factor alpha and the failing human heart. Curr Opin Cardiol. 1999 May; 14(3):206-10.
Score: 0.028
-
Cytokines in heart failure: pathogenetic mechanisms and potential treatment. Proc Assoc Am Physicians. 1999 Sep-Oct; 111(5):423-8.
Score: 0.007